Mater

Mater is a prominent Australian not-for-profit healthcare, research, and education organization based in Brisbane, Queensland. Established in 1906 by the Sisters of Mercy, it operates an extensive network of public and private hospitals and is a leader in clinical and translational medicine. Its research division, Mater Research, follows a "bench-to-bedside" approach, focusing on oncology, mother and baby health, neurosciences, and chronic diseases. The organization manages an active clinical trial infrastructure and a proprietary drug development pipeline, featuring a Phase 1 antibody-based radiotherapy targeting CDCP1 for advanced cancers. Mater is a founding partner of the Translational Research Institute (TRI) and collaborates extensively with academic and industry partners to commercialize medical innovations.